Pipeline

Our pipeline

Program Compound Lead Indications Drug Discovery Preclinical Study Phase I Trial POC
CLK inhibitor CTX-712 AML, MDS, Solid cancers
MALT1 inhibitor CTX-177 Non-Hodgkin Lymphoma
CDK12 inhibitor - Solid cancers
GCN2 inhibitor - AML, MDS, Solid cancers
Undisclosed - Undisclosed